DAWN
Day One Biopharmaceuticals, Inc.Company Information
- Company Name
- Day One Biopharmaceuticals, Inc.
- CIK
- CIK0001845337
- Category
- Large accelerated filer
- Ticker: Exchange
- DAWN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- DAWN
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-10-20
- Last sale
- 2026-02-17
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 140,546
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 78,576,724
- Shares outstanding
- 103,205,703
- Ownership
- 76.14%
Earnings Market Reaction
- Filing date
- 2026-02-24
- Price on filing date
- —
- 1-month reaction
- 78.30%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 197 | 43 | 36 | 33 | 125 | 423 | 240 | 270 | 231 | 241 | 189 | 49 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 485 | 490 | 494 | 509 | 562 | 581 | 383 | 326 | 375 | 413 | 450 | 322 | ||||||
| Short Term Investments | 244 | 408 | 417 | 440 | 407 | 136 | 122 | 48 | 136 | 164 | 254 | 269 | ||||||
| Receivables Net Current | 27 | 17 | 20 | 18 | 14 | 9 | 9 | - | 0 | - | - | - | ||||||
| Inventory Net | 6 | 7 | 7 | 4 | 3 | 3 | 0 | - | 0 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 11 | 15 | 15 | 14 | 13 | 11 | 12 | 8 | 9 | 8 | 7 | 4 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 3 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | 18 | 19 | 20 | 20 | 16 | 16 | 17 | - | 0 | - | - | - | ||||||
| Assets | 508 | 514 | 519 | 534 | 583 | 601 | 400 | 327 | 376 | 414 | 451 | 324 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 4 | 6 | 5 | 3 | 3 | 3 | 6 | 5 | 3 | 3 | 5 | 5 | ||||||
| Accrued Liabilities And Other Liabilities | 55 | 48 | 44 | 44 | 69 | 35 | 87 | 25 | 27 | 21 | 20 | 18 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 61 | 56 | 51 | 48 | 73 | 40 | 94 | 30 | 30 | 24 | 25 | 23 | ||||||
| Deferred Revenue Current | 2 | 2 | 2 | 2 | 2 | 1 | - | - | 0 | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | - | - | 0 | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | - | - | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 0 | 1 | 1 | 1 | 1 | - | - | - | 0 | - | - | - | ||||||
| Liabilities | 67 | 63 | 58 | 55 | 80 | 45 | 94 | 30 | 30 | 25 | 25 | 23 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,102 | 1,091 | 1,081 | 1,070 | 1,057 | 1,044 | 832 | 818 | 805 | 794 | 784 | 612 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 441 | 451 | 461 | 480 | 503 | 555 | 307 | 297 | 347 | 390 | 426 | 300 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | -0 | -0 | 0 | -0 | -0 | -0 | 0 | -0 | -0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -661 | -640 | -620 | -590 | -554 | -488 | -525 | -521 | -459 | -404 | -358 | -312 | ||||||
| Liabilities And Stockholders Equity | 508 | 514 | 519 | 534 | 583 | 601 | 400 | 327 | 376 | 414 | 451 | 324 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 103 | 103 | 102 | 101 | 101 | 101 | 88 | 87 | 87 | 87 | 87 | 74 | ||||||
| Shares Outstanding | 103 | 103 | 102 | 101 | 101 | 101 | 88 | 87 | 87 | 87 | 87 | 74 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDay One Biopharmaceuticals, Inc. (DAWN) — SEC Financial Statements & Analysis
Day One Biopharmaceuticals, Inc. (DAWN) is a pharmaceutical preparations company, incorporated in DE. Day One Biopharmaceuticals, Inc. trades on Nasdaq as: DAWN. Day One Biopharmaceuticals, Inc. (DAWN)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-02-24. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), On profitability, Day One Biopharmaceuticals, Inc. posts an operating margin of -82.20%, a net margin of -69052.44%, a Return on Equity (ROE) of -22739.81%, a Return on Assets (ROA) of -19681.01%, and a Return on Invested Capital (ROIC) of -34.53%. Per share, it reports EPS of $-1039.88, diluted EPS of $-1039.88, free cash flow per share of $-1.01, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 18.50% year-over-year, net income growth of 112283.76% year-over-year, and EPS growth of 101425.49% year-over-year. On the balance sheet, it maintains a current ratio of 8.02x, a quick ratio of 7.73x, working capital of $424.58M, a debt-to-equity ratio of 0.15x, a debt ratio of 0.13, an interest coverage ratio of -71.16x, free cash flow of $-104.08M (TTM), and net debt of $-84.82M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-1039.88
- ROE TTM
- -22739.81%
- ROA TTM
- -19681.01%
- Debt To Equity
- 0.15x
- Free Cash Flow TTM
- $-104.08M
- Net Revenue TTM Growth 1Y
- 18.50%
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Day One Biopharmaceuticals, Inc. in?
Day One Biopharmaceuticals, Inc. (DAWN) operates in the Pharmaceutical Preparations industry.
What exchange does DAWN trade on?
Day One Biopharmaceuticals, Inc. (DAWN) trades on the Nasdaq.
Where is Day One Biopharmaceuticals, Inc. incorporated?
Day One Biopharmaceuticals, Inc. is incorporated in DE.
When was Day One Biopharmaceuticals, Inc. (DAWN)'s most recent SEC filing?
Day One Biopharmaceuticals, Inc. (DAWN)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-02-24.
What is DAWN's EPS (earnings per share)?
Day One Biopharmaceuticals, Inc. (DAWN)'s trailing twelve month EPS is $-1039.88 as of 2025-12-31.
What is DAWN's ROE (return on equity)?
Day One Biopharmaceuticals, Inc. (DAWN)'s trailing twelve month Return on Equity (ROE) is -22739.81% as of 2025-12-31.
What is DAWN's ROA (return on assets)?
Day One Biopharmaceuticals, Inc. (DAWN)'s trailing twelve month Return on Assets (ROA) is -19681.01% as of 2025-12-31.
What is DAWN's ROIC (return on invested capital)?
Day One Biopharmaceuticals, Inc. (DAWN)'s trailing twelve month Return on Invested Capital (ROIC) is -34.53% as of 2025-12-31.